Takeda, Lundbeck seek FDA nod for depression drug

OSAKA, Japan — Drug makers Takeda Pharmaceutical and H. Lundbeck have applied with the Food and Drug Administration for a new drug to treat depression in adults.

Japan-based Takeda and Denmark-based Lundbeck announced the submission of a new drug application for Lu AA21004 (vortioxetine) for major depressive disorder.

"The prevalence and complexity of major depressive disorder remains a growing concern for physicians and those living with the condition," Takeda Global Research & Development Center president Azmi Nabulsi said. "This NDA submission is a critical milestone for Takeda and our partner, Lundbeck, demonstrating our commitment to those living with and treating this condition."

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.